Health and Human Services may open a path for specialty pharmacies to compound certain synthetic peptides that are not FDA approved, according to reporting on the proposed interim access mechanism. Support for the idea is said to come from Health Secretary Robert F. Kennedy Jr., who told Joe Rogan's podcast in February 2026 that he is a "big fan" of the injectables.

Peptides are short chains of amino acids, or "kind of like the building blocks of proteins," says Dr. Alison Dempsey, a dermatologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital. Some occur naturally in the body, including insulin and endorphins, while others are made in labs: GLP-1 drugs such as Ozempic are lab-made peptides that carry FDA approval.

Where the attention has moved

The compounds driving the current wave are the injectables without that approval, mainly BPC-157 and GHK-Cu, according to Dr. Pieter Cohen of Harvard Medical School and Cambridge Health Alliance. GHK-Cu is promoted as an anti-aging option, while BPC-157 has shown anti-inflammatory potential in some animal and lab research with no large-scale human study of its safety or effectiveness.

Cohen points to the runaway success of GLP-1s for diabetes and weight loss as one reason interest is climbing across the category. That is a reasonable read, and it is also why the category now contains two very different things sharing one word.

Why the FDA list matters

The FDA maintains a list of injectables that "may present significant safety risks," and several peptides are on it, BPC-157 included. "There are a few reasons why, but one of the main ones is the absence of evidence," said Dr. Caleb Alexander, an epidemiologist and physician at the Johns Hopkins Bloomberg School of Public Health, pointing to the lack of rigorous human trials.

The gray market problem

Alexander notes that social media sellers and gray-market channels pitch sweeping health benefits. Cohen warns that buying through those channels can mean the wrong compound, the wrong dose, or products contaminated with bacteria or other problematic substances.

Bottom line

Dempsey's summary is the sharpest line in the story: "when it comes to peptides marketing, word of mouth has strongly surpassed where we are with any type of research." What to watch is whether HHS formalizes an interim access policy, and how the FDA responds on the peptides it has already flagged.